Early response to treatment with Glivec®detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor

被引：1

作者：

Bolton, R. C. Delgado ^{[1
,2
]}

Candil, A. Ortega ^{[2
]}

Castejon, M. J. Perez ^{[2
]}

Garcerant, M. ^{[3
]}

Martin, M. N. Cabrera ^{[2
]}

Gutierreza, L. Lapena ^{[1
]}

Delgado, J. L. Carreras ^{[1
]}

机构：

[1] Hosp Clin San Carlos, Nucl Med Serv, Madrid 28040, Spain

[2] Inst PET FOCUSCAN, Madrid, Spain

[3] Hosp Univ Doce Octubre, Nucl Med Serv, Madrid, Spain

来源：

REVISTA ESPANOLA DE MEDICINA NUCLEAR | 2008年 / 27卷 / 02期

关键词：

PET; F-18-FDG; gastrointestinal stromal tumor; Glivec (R); GIST;

D O I：

10.1157/13117192

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

We present the case of a male patient with gastrointestinal stromal tumor (GIST) in whom we conducted two F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) studies, the first one prior to beginning the treatment with Glivec (R) and the second after one month of treatment. The first 18F-FDG PET scan detected multiple FDG avid foci in distal esophagus, liver and in an interaortocava lymph node. The second 18F-FDG PET showed very good response to therapy, with an almost complete disease remission. After 23 months of follow-up, the early response to treatment detected by F-18-FDG PET was confirmed. The Utility Of F-18-FDG PET in the evaluation of response to treatment in GIST is discussed and compared with CT.

引用

页码：112 / 117

页数：6

共 17 条

[1]

Antoch G, 2004, J NUCL MED, V45, P357

[2] We should desist using RECIST, at least in GIST [J].

Benjamin, Robert S. ;

Choi, Haesun ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Charnsangavej, Chuslip .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764

[3]

BENJAMIN RS, 2006, J CLIN ONCOL S, P9506

[4]

BOLTON RCD, 2007, ONCOLOGIA, V30, P138

[5] CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings [J].

Choi, H ;

Charnsangavej, C ;

Faria, SD ;

Tamm, EP ;

Benjamin, RS ;

Johnson, MM ;

Macapinlac, HA ;

Podoloff, DA .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 183 (06) :1619-1628

[6] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[7] Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors [J].

Garcia-Gonzalez, J. ;

Salmon, A. Sanchez ;

Manrique, C. Areses ;

Mateos, L. Leon ;

Salgado, J. Barandela ;

Lopez, R. Lopez .

REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2007, 26 (02) :100-102

[8]

Gayed I, 2004, J NUCL MED, V45, P17

[9] The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate [J].

Goerres, GW ;

Stupp, R ;

Barghouth, G ;

Hany, TF ;

Pestalozzi, B ;

Dizendorf, E ;

Schnyder, P ;

Luthi, F ;

von Schulthess, GK ;

Leyvraz, S .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (02) :153-162

[10] Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET [J].

Jager, PL ;

Gietema, JA ;

van der Graaf, WTA .

NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (05) :433-438

← 1 2 →